Table 1 Influence of benzo[a]pyrene DNA adduct by various compounds
From: Modulation of benzo[a]pyrene–DNA adduct formation by CYP1 inducer and inhibitor
Reference | Cells/organs | Compound | Physiological property | Modulation of BaP adduct |
|---|---|---|---|---|
de Waard et al. [20] | Caco-2 (human colorectal carcinoma) | TCDD | AhR agonist | reduction |
Gelhaus SL [21] | H358 (human lung carcinoma) | TCDD | AhR agonist | enhancement |
Wu Q et al. [19] | mouse liver | TCDD | AhR agonist | reduction |
Harrigan JA et al. [23] | rat lung and liver (ex vivo) | TCDD | AhR agonist | enhancement |
Shiizaki K et al. [24] | HepG2 (human hepatoma) | TCDD | AhR agonist | reduction |
Hodek P et al. [15] | rat liver/small intestine | BNF | AhR agonist | enhancement |
Chang KW et al. [25] | A427 and CL3 (human lung carcinoma) | BNF ANF | AhR agonist AhR antagonist/CYP1A1 inhibitor | enhancement reduction |
Mohebati A et al. [16] | MSK-Leuk | ANF carnosol | AhR antagonist/CYP1A1 inhibitor (AhR antagonist) | reduction reduction |
Takemura H et al. [26] | MCF-7 (human breast adenocarcinoma) | chrysoeriol | CYP1A1/1B1 inhibitor | reduction |
Wen X et al. [27] | SCC-9 (human squamous carcinoma) | 5,7-DMF | CYP1B1 inhibitor | reduction |
Kang ZC et al. [14] | HepG2 | quercetin | AhR activator | reduction |
Vanhees K et al. [54] | mouse liver (ex vivo) | quercetin | AhR activator | reduction |
Revel A et al. [17] | mouse lung | resveratrol | AhR antagonist | reduction |
Sehgal A et al. [28] | mouse liver and lung | curcumin | CYP1A1 inhibitor/(AhR agonist) | reduction |
Kleiner HE et al. [29] | MCF-7 (human breast adenocarcinoma) | coumarins | CYP1A1/1B1 inhibitor | reduction |